HER2 Support Group Forums - View Single Post - her2+ breast cancer tied to disturbed circadian gene expression

Lani · 03-23-2009, 11:22 PM

I think you got a bit confused -- as they found that:
HOMOGENOUS expression of PER2 or BMAL1 is significantly associated with lymph node metastasis and poor prognosis....It was PER2 HETEROGENOUS expression correlates with <2+ c-erbB2 immunohistochemical reaction. Heterogeneous expression of CLOCK is associated significantly with 3-year survival.

I think they mean HOMOGENOUS PER2 which was assoctd with poor prognosis

HETEROGENOUS expression of PER2 seemed to be correlated with NON smplfied her2 expression or nonexpression and in contradistinction a better prognosis, unless one was hetergenous for PER but homogenous for BMALI in which case one's prognosis would be poor and one would be more likely to have more involved lymph nodes

I would have to go back to the original article ( I am travelling at the moment) to see if their comment on
eterogeneous expression of CLOCK is associated significantly with 3-year survival (means is associated significantly with GOOD vs POOR 3 year survival and how that correlated with her2

The sentence you didn't comment on also had import for her2+s:
As Drs. Pegram and Slamon say her2 amplification is associated with a downregulation of ER --so the other sentence you did not quote, went right along with that:
Promoter methylation of the PER1 correlates with c-erbB2 immunohistochemical reaction of >/=2+ (p = 0.012) and has a strong inverse correlation with estrogen receptor positivity (p = 0.016).

Hope this clarifies things a bit!

03-23-2009, 11:22 PM	#6
Lani Senior Member Join Date: Mar 2006 Posts: 4,780	Steph N I think you got a bit confused -- as they found that: HOMOGENOUS expression of PER2 or BMAL1 is significantly associated with lymph node metastasis and poor prognosis....It was PER2 HETEROGENOUS expression correlates with <2+ c-erbB2 immunohistochemical reaction. Heterogeneous expression of CLOCK is associated significantly with 3-year survival. I think they mean HOMOGENOUS PER2 which was assoctd with poor prognosis HETEROGENOUS expression of PER2 seemed to be correlated with NON smplfied her2 expression or nonexpression and in contradistinction a better prognosis, unless one was hetergenous for PER but homogenous for BMALI in which case one's prognosis would be poor and one would be more likely to have more involved lymph nodes I would have to go back to the original article ( I am travelling at the moment) to see if their comment on eterogeneous expression of CLOCK is associated significantly with 3-year survival (means is associated significantly with GOOD vs POOR 3 year survival and how that correlated with her2 The sentence you didn't comment on also had import for her2+s: As Drs. Pegram and Slamon say her2 amplification is associated with a downregulation of ER --so the other sentence you did not quote, went right along with that: Promoter methylation of the PER1 correlates with c-erbB2 immunohistochemical reaction of >/=2+ (p = 0.012) and has a strong inverse correlation with estrogen receptor positivity (p = 0.016). Hope this clarifies things a bit!